Monopar Therapeutics (NASDAQ:MNPR) Trading Down 8.9% – What’s Next?

Monopar Therapeutics Inc. (NASDAQ:MNPR)’s stock price was down 8.9% on Thursday . The company traded as low as $101.00 and last traded at $102.4440. 39,515 shares traded hands during mid-day trading, a decline of 81% from the average session volume of 210,904 shares. The stock had previously closed at $112.48.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on the stock. Cantor Fitzgerald reissued an “overweight” rating on shares of Monopar Therapeutics in a research report on Wednesday, July 15th. Zacks Research upgraded shares of Monopar Therapeutics from a “hold” rating to a “strong-buy” rating in a report on Monday, July 13th. Piper Sandler set a $105.00 target price on shares of Monopar Therapeutics in a research note on Tuesday, June 2nd. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Monopar Therapeutics in a research note on Friday, July 17th. Finally, HC Wainwright lifted their target price on shares of Monopar Therapeutics from $105.00 to $125.00 and gave the company a “buy” rating in a report on Wednesday. Three equities research analysts have rated the stock with a Strong Buy rating, ten have assigned a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Monopar Therapeutics presently has an average rating of “Buy” and a consensus target price of $112.08.

Monopar Therapeutics Stock Performance

The firm has a market cap of $736.02 million, a P/E ratio of -57.83 and a beta of 1.46. The stock has a fifty day simple moving average of $80.50 and a 200 day simple moving average of $66.67.

Monopar Therapeutics (NASDAQ:MNPR) last announced its quarterly earnings results on Thursday, May 14th. The company reported ($0.46) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.87) by $0.41. Research analysts predict that Monopar Therapeutics Inc. will post -2.82 earnings per share for the current year.

Institutional Trading of Monopar Therapeutics

A number of large investors have recently made changes to their positions in MNPR. Virtu Financial LLC bought a new stake in Monopar Therapeutics in the 4th quarter worth approximately $654,000. Siren L.L.C. raised its stake in Monopar Therapeutics by 27.2% during the 1st quarter. Siren L.L.C. now owns 270,118 shares of the company’s stock valued at $14,800,000 after buying an additional 57,820 shares during the last quarter. Walleye Capital LLC bought a new position in shares of Monopar Therapeutics during the 1st quarter valued at $3,458,000. Your Advocates Ltd. LLP bought a new position in shares of Monopar Therapeutics during the 1st quarter valued at $183,000. Finally, Russell Investments Group Ltd. purchased a new position in shares of Monopar Therapeutics in the 3rd quarter worth $28,000. 1.83% of the stock is currently owned by institutional investors.

About Monopar Therapeutics

Monopar Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of novel targeted radiotherapeutics and next-generation antibody-drug conjugates for the treatment of cancer. The company’s core technology leverages a pretargeted radioimmunotherapy (PRIT) platform designed to deliver potent radioisotopes to tumor cells while minimizing exposure to healthy tissues. By combining small-molecule binding agents with specialized radioisotopes, Monopar aims to improve the therapeutic index of radiation-based cancer therapies.

The company’s pipeline includes multiple oncology candidates in various stages of preclinical and early clinical development.